Acute promyelocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute promyelocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia https://clinicaltrials.eu/trial/qtx-2101-and-arsenic-trioxide-in-newly-diagnosed-low-risk-acute-promyelocytic-leukemia-in-adult-patients/ Sat, 30 May 2026 04:03:47 +0000 https://clinicaltrials.eu/trial/qtx-2101-and-arsenic-trioxide-in-newly-diagnosed-low-risk-acute-promyelocytic-leukemia-in-adult-patients/ This clinical study is being done in Acute Promyelocytic Leukemia, a rare type of blood cancer. The treatment being studied is QTX-2101, taken by mouth as a capsule, and it is given together with all-trans retinoic acid, a medicine that helps leukemia cells mature into normal blood cells. The study also compares this approach with arsenic trioxide given through a vein, which is a standard treatment for this disease. The purpose of the study is to understand how well this treatment works and how safe it is.

The study is designed for adults with newly diagnosed, low-risk disease. Treatment is given in phases over time, including an early treatment period and later treatment cycles called consolidation, which are used to help keep the disease under control after the first response. During the study, blood tests, heart checks, and other routine medical checks are done, and side effects are watched closely. The study also looks at how the body handles QTX-2101 and whether the leukemia goes away to a very deep level, meaning no clear signs of the cancer marker PML/RARA can be found in the bone marrow.

]]> Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia https://clinicaltrials.eu/trial/study-of-arsenic-trioxide-tretinoin-and-a-drug-combination-for-children-and-adolescents-with-acute-promyelocytic-leukemia/ Thu, 07 May 2026 05:47:12 +0000 https://clinicaltrials.eu/trial/study-of-arsenic-trioxide-tretinoin-and-a-drug-combination-for-children-and-adolescents-with-acute-promyelocytic-leukemia/ This study looks at acute promyelocytic leukemia (APL) in children and adolescents. APL is a blood cancer that starts in very early white blood cells. The purpose of the study is to learn how well treatment works and how safe it is for young people with newly diagnosed APL. The treatment uses arsenic trioxide together with tretinoin, and in some patients with higher-risk disease it also includes gemtuzumab ozogamicin. Other medicines listed in the study materials include cytarabine, methotrexate, and methylprednisolone, which may be used as part of the treatment plan or support care. Some medicines are given by mouth and others are given into a vein or into the fluid around the spine, depending on the treatment step.

The study follows a treatment course made up of several phases. At first, treatment is given to bring the leukemia under control. After that, more treatment is given over time to help keep the disease from returning. Some children may receive only the main drug combination, while others may receive an added medicine based on the type of APL and the level of risk. During the study, doctors watch for side effects and monitor how the disease responds to treatment.

The study is designed for newly diagnosed APL in children and adolescents and compares treatment approaches for different risk groups. The study also examines whether the treatment causes any serious problems and how long children stay in the hospital during therapy.

]]>